英文简介

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.
OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.

中文简介

肿瘤免疫学研究自然或治疗诱导的癌症识别，以及肿瘤发生、炎症和免疫监测之间复杂的相互作用。我们现在创建了一本新的、备受瞩目的期刊《OncoImmunology》，专门研究肿瘤免疫学。最近的进展允许抗癌免疫疗法的首次临床演示（和FDA批准）。人们也越来越怀疑，出乎意料的是，目前使用的许多化疗药物的疗效取决于免疫效应器的积极作用。用一个激烈的比喻，应用成功的化疗（或放射治疗）方案的肿瘤学家利用了免疫系统识别肿瘤特异性或肿瘤相关抗原并控制癌症（干）细胞生长的能力，而不知道看不见的援助之手。因此，免疫生物标志物在确定癌症预后和预测化疗疗效方面变得越来越重要。也有充分的理由支持将传统抗癌疗法与免疫疗法相结合。
OncoImmunology将接受肿瘤免疫学基础、转化和临床领域的高调提交。欢迎提交关于实体癌或血液癌、炎症、先天性和获得性免疫反应的意见书。

中科院分区